Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

Shares of NASDAQ:BDRX opened at $1.16 on Friday. Biodexa Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $44.40. The business has a fifty day moving average of $2.29 and a two-hundred day moving average of $4.84.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises approximately 0.6% of Sabby Management LLC’s holdings, making the stock its 10th biggest holding. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.